Stock CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Creative Medical Technology Holdings, Inc. Stock

Equities

CELZ

US22529Y4089

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
4.995 USD -3.94% Intraday chart for Creative Medical Technology Holdings, Inc. -10.72% +8.35%
Mar. 22 Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023. CI
Mar. 22 Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials (USD)

Sales 2024 * - Sales 2025 * 563K Capitalization 6.78M
Net income 2024 * -6M Net income 2025 * -6M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 12 x
P/E ratio 2024 *
-1.11 x
P/E ratio 2025 *
-1.38 x
Employees 4
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.33%
More Fundamentals * Assessed data

Chart Creative Medical Technology Holdings, Inc.

Dynamic Chart

Latest news about Creative Medical Technology Holdings, Inc.

Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023. CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Creative Medical Shares Rise 37% After FDA Authorization for CELZ-201 DJ
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access CI
Creative Medical Technology Holdings Gets US FDA Orphan Drug Designation; Shares Rise MT
Private Payrolls Data, Upcoming Powell Testimony Drive Higher Premarket Action for US Equity Futures MT
Creative Medical Shares Rally Premarket on FDA Orphan Designation DJ
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of Powell Testimony MT
Top Premarket Gainers MT
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem CI
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023. CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain CI
Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem? (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain CI
Top Premarket Gainers MT
More news

Analyst Recommendations on Creative Medical Technology Holdings, Inc.

Roth Capital Starts Creative Medical Tech Holdings at Buy with $10 Price Target MT
More recommendations

Press releases Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings Provides Corporate Update BU
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access BU
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy BU
Creative Medical Technology Holdings Provides Corporate Update PR
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine using AlloStem Novel Cell Therapy to Treat Chronic Lower Back Pain AQ
More press releases

Quotes and Performance

1 day-3.94%
1 week-10.72%
Current month-4.13%
1 month-6.81%
3 months+12.65%
6 months+2.99%
Current year+8.35%
More quotes

Highs and lows

1 week
4.90
Extreme 4.9
5.62
1 month
4.90
Extreme 4.9
5.85
Current year
3.93
Extreme 3.93
10.28
1 year
3.93
Extreme 3.93
10.28
3 years
3.30
Extreme 3.3
251.50
5 years
3.30
Extreme 3.3
7 125.18
10 years
3.30
Extreme 3.3
525 013.13
More quotes

Managers and Directors - Creative Medical Technology Holdings, Inc.

Managers TitleAgeSince
Timothy Warbington CEO
 Chief Executive Officer 63 16-05-17
Donald Dickerson DFI
 Director of Finance/CFO 59 16-01-31
Courtney Bartlett CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Susan Snow BRD
 Director/Board Member 67 21-12-01
Donald Dickerson DFI
 Director of Finance/CFO 59 16-01-31
Timothy Warbington CEO
 Chief Executive Officer 63 16-05-17
More insiders

Quotes

Date Price Change Volume
24-04-17 4.995 -3.94% 19,042
24-04-16 5.2 -0.19% 4,320
24-04-15 5.21 0.00% 7,851
24-04-12 5.21 -4.67% 4,124
24-04-11 5.465 -2.32% 6,100

Delayed Quote Nasdaq, April 17, 2024 at 04:30 pm EDT

More quotes

Company Profile

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
4.995 USD
Average target price
30 USD
Spread / Average Target
+500.60%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock Creative Medical Technology Holdings, Inc.
+8.35% 7.05M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.39% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.61% 96.09B
ARGENX SE Stock argenx SE
-1.02% 22.05B
BIONTECH SE Stock BioNTech SE
-18.14% 20.81B
GENMAB A/S Stock Genmab A/S
-6.87% 19.06B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.70% 16.05B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.89% 14.01B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.12% 13.38B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+22.25% 11.01B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CELZ Stock